{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:16:44Z","timestamp":1788833804372,"version":"build-2803163510"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"\n Importance<\/jats:title>\n The Southern Community Cohort Study (SCCS) Polypill Trial showed that a cardiovascular polypill (a single pill containing a statin and 3 half-standard dose antihypertensive medications) effectively controls cardiovascular disease (CVD) risk factors in a majority Black race and low-income population. The cost-effectiveness of polypill treatment in this population has not been previously studied.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the cost-effectiveness of the cardiovascular polypill.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A discrete-event simulation version of the well-established CVD policy model simulated clinical and economic outcomes of the SCCS Polypill Trial from a health care sector perspective. A time horizon of 10 years was adopted. Polypill treatment was priced at $463 per year in the base-case analysis. Model input data were derived from the National Health and Nutrition Examination Survey, Medical Expenditure Panel Survey, pooled longitudinal cohort studies, the SCCS Polypill Trial, and published literature. Two cohorts were analyzed: an SCCS Polypill Trial\u2013representative cohort of 100\u202f000 individuals and all trial-eligible non-Hispanic Black US adults. Study parameters and model inputs were varied extensively in 1-way and probabilistic sensitivity analysis.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Polypill treatment or usual care.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Primary outcomes were direct health care costs (US dollar 2023) and quality-adjusted life-years (QALYs), both discounted 3% annually, and the incremental cost per QALY gained.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the trial-representative cohort of 100\u202f000 individuals (mean [SD] age, 56.9 [5.9] years; 61\u202f807 female [61.8%]), polypill treatment was projected to yield a mean of 1190 (95% uncertainty interval, 287-2159) additional QALYs compared with usual care, at a cost of approximately $10\u202f152\u202f000. Hence, polypill treatment was estimated to cost $8560 per QALY gained compared with usual care and was high value (&amp;lt;$50\u202f000 per QALY gained) in 99% of simulations. Polypill treatment was estimated to be high value when priced at $559 or less per year and cost saving when priced at $443 or less per year. In almost all sensitivity analyses, polypill treatment remained high value. In a secondary analysis of 3 602 427 trial-eligible non-Hispanic Black US adults (mean [SD] age, 55.4 [7.6] years; 2 006 597 female [55.7%]), polypill treatment was high value, with an estimated cost of $13 400 per QALY gained.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this economic evaluation suggest that polypill treatment could be a high value intervention for a low-income, majority Black population with limited access to health care services. It could additionally reduce health disparities.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2024.4812","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:01:15Z","timestamp":1736334075000},"page":"224","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population"],"prefix":"10.1001","volume":"10","author":[{"given":"Ciaran N.","family":"Kohli-Lynch","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Moran","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv S.","family":"Kazi","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts"},{"name":"Division of Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bibbins-Domingo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of California, San Francisco, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Jordan","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Psychiatry & Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"French","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"},{"name":"Veterans Affairs Health Services Research and Development Service, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon K.","family":"Bellows","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"hoi240081r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.18150","article-title":"Trends in cardiovascular disease prevalence by income level in the US.","volume":"3","author":"Abdalla","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"hoi240081r2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11886-022-01826-x","article-title":"Racial and ethnic disparities in hypertension: barriers and opportunities to improve blood pressure control.","volume":"25","author":"Abrahamowicz","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"hoi240081r3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/jamacardio.2023.0228","article-title":"Prevalence of statin use for primary prevention of atherosclerotic cardiovascular disease by race, ethnicity, and 10-year disease risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.","volume":"8","author":"Jacobs","year":"2023","journal-title":"JAMA Cardiol"},{"key":"hoi240081r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchy.2020.100044","article-title":"Prevalence and control rates of hypertension in the USA: 2017-2018.","volume":"6","author":"Chobufo","year":"2020","journal-title":"Int J Cardiol Hypertens"},{"issue":"6","key":"hoi240081r5","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1161\/HYPERTENSIONAHA.121.17570","article-title":"Racial\/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the US, 2013 to 2018.","volume":"78","author":"Aggarwal","year":"2021","journal-title":"Hypertension"},{"issue":"2","key":"hoi240081r6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamacardio.2021.4996","article-title":"Association of differences in treatment intensification, missed visits, and scheduled follow-up interval with racial or ethnic disparities in blood pressure control.","volume":"7","author":"Fontil","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi240081r7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212117","article-title":"Racial and ethnic disparities in medication adherence among privately insured patients in the US.","volume":"14","author":"Xie","year":"2019","journal-title":"PLoS One"},{"key":"hoi240081r8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pcad.2022.01.005","article-title":"Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: a systematic review and meta-analysis of randomized controlled trials.","volume":"73","author":"Rao","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"hoi240081r9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/heartjnl-2018-313108","article-title":"Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomized clinical trials.","volume":"105","author":"Selak","year":"2019","journal-title":"Heart"},{"issue":"12","key":"hoi240081r10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1815359","article-title":"Polypill for cardiovascular disease prevention in an underserved population.","volume":"381","author":"Mu\u00f1oz","year":"2019","journal-title":"N Engl J Med"},{"key":"hoi240081r11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijcard.2022.04.085","article-title":"Polypill for cardiovascular disease prevention: systematic review and meta-analysis of randomized controlled trials.","volume":"360","author":"Mohamed","year":"2022","journal-title":"Int J Cardiol"},{"issue":"5","key":"hoi240081r12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.pcad.2019.10.006","article-title":"Implications of cost-effectiveness analyses of lipid-lowering therapies: from the policy-maker\u2019s desk to the patient\u2019s bedside.","volume":"62","author":"Kazi","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"issue":"24","key":"hoi240081r13","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1161\/CIRCULATIONAHA.120.051683","article-title":"Cost-effectiveness of hypertension treatment by pharmacists in Black barbershops.","volume":"143","author":"Bryant","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"hoi240081r14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1161\/HYPERTENSIONAHA.122.20292","article-title":"Effectiveness and cost-effectiveness of team-based care for hypertension: a meta-analysis and simulation study.","volume":"80","author":"Bryant","year":"2023","journal-title":"Hypertension"},{"issue":"11","key":"hoi240081r15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41371-023-00811-3","article-title":"Cost-effectiveness analysis of initial treatment with single-pill combination antihypertensive medications.","volume":"37","author":"Bryan","year":"2023","journal-title":"J Hum Hypertens"},{"issue":"2","key":"hoi240081r16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032370","article-title":"Effectiveness of hypertension management strategies in SPRINT-eligible US adults: a simulation study.","volume":"13","author":"Zhang","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"hoi240081r17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events.","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"20","key":"hoi240081r18","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jacc.2021.08.065","article-title":"Cost-effectiveness of lipid-lowering treatments in young adults.","volume":"78","author":"Kohli-Lynch","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hoi240081r19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005624","article-title":"Clinic-based strategies to reach US million hearts 2022 blood pressure control goals.","volume":"12","author":"Bellows","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"24","key":"hoi240081r20","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"hoi240081r21","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNa guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hoi240081r22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"21","key":"hoi240081r24","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on performance measures and task force on practice guidelines.","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"hoi240081r26","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","article-title":"Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies.","volume":"338","author":"Law","year":"2009","journal-title":"BMJ"},{"issue":"7404","key":"hoi240081r27","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials.","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"hoi240081r28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008226.pub3","article-title":"Lipid-lowering efficacy of atorvastatin.","volume":"2015","author":"Adams","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"10017","key":"hoi240081r30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"hoi240081r31","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive vs standard blood-pressure control.","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"1537","key":"hoi240081r32","doi-asserted-by":"publisher","first-page":"n1537","DOI":"10.1136\/bmj.n1537","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"hoi240081r33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study.","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"hoi240081r34","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association.","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"hoi240081r35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug\u2014systematic review of randomized placebo-controlled trials to aid individual patient choice.","volume":"21","author":"Finegold","year":"2014","journal-title":"Eur J Prev Cardiol"},{"issue":"10022","key":"hoi240081r36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"hoi240081r37","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance.","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"issue":"7653","key":"hoi240081r38","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/bmj.39553.670231.25","article-title":"Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.","volume":"336","author":"Vrijens","year":"2008","journal-title":"BMJ"},{"issue":"6","key":"hoi240081r39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.18553\/jmcp.2016.22.6.685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk.","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"9841","key":"hoi240081r40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials.","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"hoi240081r41","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamacardio.2019.2851","article-title":"Cost-effectiveness of low-density lipoprotein cholesterol level-guided statin treatment in patients with borderline cardiovascular risk.","volume":"4","author":"Kohli-Lynch","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi240081r42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.114.001240","article-title":"Quantifying the utility of taking pills for cardiovascular prevention.","volume":"8","author":"Hutchins","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"hoi240081r43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006505","article-title":"Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.","volume":"5","author":"Hutchins","year":"2015","journal-title":"BMJ Open"},{"issue":"15","key":"hoi240081r44","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016174","article-title":"Impact of self-monitoring of blood pressure on processes of hypertension care and long-term blood pressure control.","volume":"9","author":"Bryant","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"hoi240081r45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-008018","article-title":"Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.","volume":"5","author":"Wood","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"hoi240081r48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"issue":"10","key":"hoi240081r49","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40273-020-00936-0","article-title":"Novel Treatment strategies for secondary prevention of cardiovascular disease: a systematic review of cost-effectiveness.","volume":"38","author":"Marquina","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"hoi240081r50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182625","article-title":"Cost-effectiveness analysis of use of a polypill vs usual care or best practice for primary prevention in people at high risk of cardiovascular disease.","volume":"12","author":"Jowett","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"hoi240081r51","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5993\/AJHB.44.2.10","article-title":"Social risk factors for medication nonadherence: findings from the CARDIA study.","volume":"44","author":"Oates","year":"2020","journal-title":"Am J Health Behav"},{"issue":"9","key":"hoi240081r52","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/jech-2020-214238","article-title":"Medication adherence in community-dwelling older people exposed to chronic polypharmacy.","volume":"75","author":"Franchi","year":"2021","journal-title":"J Epidemiol Community Health"},{"issue":"4","key":"hoi240081r53","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1161\/HYPERTENSIONAHA.120.16784","article-title":"Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension.","volume":"77","author":"Lee","year":"2021","journal-title":"Hypertension"},{"issue":"1","key":"hoi240081r55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0272989X15583266","article-title":"Distributional cost-effectiveness analysis: a tutorial.","volume":"36","author":"Asaria","year":"2016","journal-title":"Med Decis Making"},{"issue":"10","key":"hoi240081r56","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and costing in cost-effectiveness analysis, 1974-2018.","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"hoi240081r23","unstructured":"US Bureau of Labor Statistics. Consumer Price Index databases. Accessed February 28, 2023. https:\/\/www.bls.gov\/cpi\/data.htm"},{"key":"hoi240081r25","unstructured":"Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Accessed March 23, 2024. http:\/\/meps.ahrq.gov\/mepsweb\/"},{"key":"hoi240081r29","unstructured":"Centers for Disease Control and Prevention. National Center for Health Statistics. Accessed May 25, 2023. https:\/\/wwwn.cdc.gov\/Nchs\/Nhanes\/"},{"key":"hoi240081r46","unstructured":"Medicaid.gov. Federal upper limit\u2014Affordable Care Act. Accessed January 4, 2024. https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/federal-upper-limit\/index.html"},{"key":"hoi240081r47","unstructured":"Data.Medicaid.gov. NADAC (National Average Drug Acquisition Cost) 2024. Accessed January 5, 2024. https:\/\/data.medicaid.gov\/dataset\/99315a95-37ac-4eee-946a-3c523b4c481e"},{"key":"hoi240081r54","unstructured":"Centers for Medicare and Medicaid Services. Medicare drug price negotiation. Accessed December 7, 2023. https:\/\/www.cms.gov\/inflation-reduction-act-and-medicare\/medicare-drug-price-negotiation"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2828599\/jamacardiology_kohlilynch_2025_oi_240081_1741367266.39869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:01:44Z","timestamp":1741777304000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2828599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.4812","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}